Results 31 to 40 of about 3,353 (184)

AmpC induction by imipenem in Pseudomonas aeruginosa occurs in the absence of OprD and impacts imipenem/relebactam susceptibility

Microbiology Spectrum
In the United States, carbapenem resistance in Pseudomonas aeruginosa is linked to the regulation of chromosomal resistance determinants, AmpC and OprD.
Shawn Freed, Jr, Nancy D. Hanson
doaj   +2 more sources

Activity of imipenem/relebactam against Enterobacterales and Pseudomonas aeruginosa in Spain. SMART 2016-2020 [PDF]

, 2023
Objectives. To determine susceptibility to the novel β-lactam/β-lactamase inhibitor combination imipenem/relebactam in clinical isolates recovered from intra-abdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream (BSI) infections in the SMART (
Alicia Hernández-Cabezas, Castillo, Francisco Javier, Javier Castillo, Francisco, Jorge Calvo, García-Fernández, Sergio, Fariñas, María Carmen, Fe Tubau, Rafael Cantón, Gómez, María, Díaz-Regañón, Jazmín, Calvo, Jorge, Gálvez-Benítez, Lydia, Emilia Cercenado, Francisco Javier Castillo, Lydia Gálvez-Benítez, Fariñas Álvarez, María del Carmen, Figueroa Cerón, Ruth Esther, Fernando González Romo, Suárez-Barrenechea, Ana Isabel, Tubau, Fe, Fernández-Billón, María, García Fernández, Sergio, Ana Isabel Suárez-Barrenechea, González Romo, Fernando, Sergio García-Fernández, Jazmín Díaz-Regañón, Cantón, Rafael, María Carmen Fariñas, Carmen Farinas, Maria, María Gómez, Cercenado, Emilia, María Fernández-Billón, Hernández-Cabezas, Alicia, Ruth Esther Figueroa Cerón   +33 more
core   +2 more sources

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections [PDF]

Drugs, 2021
Imipenem/cilastatin/relebactam (Recarbrio™) is an intravenously administered combination of the carbapenem imipenem, the renal dehydropeptidase-I inhibitor cilastatin, and the novel β-lactamase inhibitor relebactam. Relebactam is a potent inhibitor of class A and class C β-lactamases, conferring imipenem activity against many imipenem-nonsusceptible ...
Mansour, Hanine, Oweini, Ahmad E. L, Chahine, Elias B., Karaoui, Lamis R.   +3 more
openaire   +6 more sources

Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018–2020

BMC Microbiology, 2023
Background Carbapenem-resistant bacteria are an increasing problem in clinical practice; thus, it is important to identify β-lactamase inhibitors (e.g., relebactam) that can restore carbapenem susceptibility.
David W. Hilbert, C. Andrew DeRyke, Mary Motyl, Meredith Hackel, Katherine Young   +4 more
doaj   +1 more source

Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa

, 2023
Purpose: Relebactam is a novel β-lactamase inhibitor, which, when combined with imipenem/cilastatin, is active against both class A and class C β-lactamases.
Delgado Valverde, María Mercedes, Hidalgo, Carmen, Portillo Calderón, Inés María, Alcalde Rico, Manuel, Pascual Hernández, Álvaro, Conejo Gonzalo, Mª Carmen, Del Toro Esperón, Carlos   +6 more
core   +1 more source

In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015–2017

Journal of Global Antimicrobial Resistance, 2020
Objectives: Antimicrobial resistance, including multidrug-resistance (MDR), is increasing, especially among Gram-negative bacilli. New agents are needed to treat infections caused by these pathogens.
James A. Karlowsky, Sibylle H. Lob, Krystyna M. Kazmierczak, Katherine Young, Mary R. Motyl, Daniel F. Sahm   +5 more
doaj   +1 more source

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors

Antibiotics, 2021
The growing emergence of drug-resistant bacterial strains is an issue to treat severe infections, and many efforts have identified new pharmacological agents.
Giacomo Luci, Francesca Mattioli, Marco Falcone, Antonello Di Paolo   +3 more
doaj   +1 more source

Predicting the Effects of Carbapenem/Carbapenemase Inhibitor Combinations against KPC-Producing Klebsiella pneumoniae in Time-Kill Experiments: Alternative versus Traditional Approaches to MIC Determination

Antibiotics, 2021
Traditionally, the antibacterial activity of β-lactam antibiotics in the presence of β-lactamase inhibitors is determined at the fixed inhibitor concentration.
Alla V. Filimonova, Maria V. Golikova, Elena N. Strukova, Yury A. Portnoy, Anastasiya A. Kuznetsova, Stephen H. Zinner   +5 more
doaj   +1 more source

A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates

Antibiotics, 2021
An increasing number of untreatable infections are recorded every year. Many studies have focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) isolates. In the present study, sulbactam/avibactam and sulbactam/
Fernando Pasteran, Jose Cedano, Michelle Baez, Ezequiel Albornoz, Melina Rapoport, Jose Osteria, Sabrina Montaña, Casin Le, Grace Ra, Robert A. Bonomo, Marcelo E. Tolmasky, Mark Adams, Alejandra Corso, Maria Soledad Ramirez   +13 more
doaj   +1 more source

Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options

Frontiers in Microbiology, 2019
Carbapenems are considered as last-resort antibiotics for the treatment of infections caused by multidrug-resistant Gram-negative bacteria. With the increasing use of carbapenems in clinical practice, the emergence of carbapenem-resistant pathogens now ...
Chau-Chyun Sheu, Chau-Chyun Sheu, Ya-Ting Chang, Ya-Ting Chang, Shang-Yi Lin, Shang-Yi Lin, Yen-Hsu Chen, Yen-Hsu Chen, Yen-Hsu Chen, Po-Ren Hsueh, Po-Ren Hsueh   +10 more
doaj   +1 more source